Audit: QRS - Pumpkin Seed Extract for Health & Longevity

Audit conducted on 16/08/2026 03:11 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol doses, time-to-effect values, benefit/risk items, contraindications, interactions, markers and qualitative items trace to explicit ER passages.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“No established target; track change from own baseline” (marker_9_target) mirrors the ER’s own hedge; “though uncommon” mirrors “if uncommon”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications keep their absolute framing; the conflicted urinary result is preserved in At-A-Glance.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come from the ER’s “Populations who should avoid” list, interactions from the ER interaction bullets, risks from Potential Risks & Side Effects.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, author names or brand names appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind are introduced.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, evidence-weighted register matching the ER throughout.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Thresholds and response definitions give the reader actionable, self-assessable anchors.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is presented as what trials used and measured, not as orders.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Protocol and monitoring cells describe tested regimens and trial endpoints.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No recommending verbs in the authored spans.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns in any authored span.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Acronyms are fully expanded (International Prostate Symptom Score, prostate-specific antigen, high-density lipoprotein cholesterol).
2.8	Information is presented in a concise and very compact manner	🟢	Items are noun phrases or short clauses; tiers are collapsed into single lines.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address in authored content.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Objective monitoring targets and dose regimens assume a proactive, self-tracking reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Trichoscopy, bladder diaries, post-void residual ultrasound and split dosing are all presented without hedging on effort.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplification toward casual use.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The conflicted urinary evidence and the preparation-dependence are surfaced rather than smoothed over.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur; the title carries “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal terms used throughout (“post-void residual”, “anaphylaxis”, “immunoglobulin E-mediated”); the plainer At-A-Glance wording is mandated by item 7.4.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings, gate titles, tier labels and column headers match verbatim (lines 446, 487, 534, 564, 578, 601, 626, 630–632, 769).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Complete set present: page_title, header_topic, header_subline_date/model, at_a_glance, action_1–3, time_1–3, benefits_, stop_items, caution_items, risks_, marker_1–9, monitoring_cadence, qualitative_item_1–6.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The non-variable spans (website="evidence_review", website="audit", website="full_review") are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section mapped into the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Oil dose for hair endpoints”, “Oil dose for urinary endpoints” and “Timing” are the ER’s bold protocol labels verbatim; marker names match the ER table verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Time-to-effect labels (“Hair endpoints”, “Urinary symptom scores”, “Blood pressure”) are lifted verbatim from the ER’s Practical Considerations time-to-effect bullet.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji in the document; the ER’s “⚠️ Conflicted” marker was correctly not carried over.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed against its ER source: benefit and risk tiers collapse to one line each, gate items are stripped to the key fact, and no ER prose is carried over verbatim.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the descriptive text on line 2 precedes the block.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is echoed elsewhere except the required header date/model.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:02" is quoted, which is required because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: pumpkin_seed_extract_2026-0825-0106_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the guideline version.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0816-0253.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the actual file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all eight keys; no stray whitespace or quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Pumpkin Seed Extract for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417, correctly entity-encoded.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 08/16/2026, matching qrs_creation_date 2026-0816.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only the title and the standard subline; the ER’s “Also known as” list was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Lines 434–438 compress the ER Conclusion’s four load-bearing points: weak mechanism, hair signal, urinary conflict, tolerability/allergy.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a separate sentence of the ER Conclusion (ER lines 497–499).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“pattern hair loss” replaces androgenetic alopecia; no acronyms used.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years or sample sizes appear.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	Only qualitative comparisons (“outperformed placebo”), no numbers.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All four items come from the ER’s “Populations who should avoid Pumpkin Seed Extract” list (ER lines 327–333).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All four ER avoid-populations are present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 567–573, four discrete <li> elements.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s trailing rationales (“given documented cross-reactivity…”, “— conditions requiring urological evaluation…”, “where any additional antiplatelet activity is unacceptable”, “on the basis of absent safety data…”) are all stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Thresholds retained: “post-void residual above 150 mL” and “platelet count below 100 × 10⁹/L”.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names four such populations and the section is correctly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All 11 items map one-to-one onto the ER’s 11 interaction bullets (ER lines 303–323).
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	No overlap with the four contraindication items.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 581–591, eleven discrete <li> elements.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s in-paren glosses (“— drugs that relax prostate and bladder-neck muscle…”, “— a mood stabiliser”) and all caution rationales are stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Named example drugs are retained for every drug class, trimmed but never dropped entirely.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names eleven such interactions and the section is correctly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from the ER Therapeutic Protocol bullets (ER lines 361–369).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Hair dose, urinary dose and timing are the only dose/administration bullets in the ER protocol; the remaining bullets are contextual rather than actionable.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct actionable aspects exist and all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	400 mg/day, 360 mg twice daily, evening/bedtime — all with ER-derived sub-lines including the alternative tested regimens.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Hair (24 weeks), urinary symptom scores (8–12 weeks) and blood pressure (6 weeks) are exactly the three named in the ER’s time-to-effect bullet.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Order follows the benefit tiers: hair density (High), urinary symptoms (Medium), blood pressure (Low).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects exist and all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Each sub-line carries an ER-sourced qualifier (non-responder rule, no separation before 8 weeks, small-trial caveat).
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect data, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All ten ER benefit headings appear, distributed across the correct tiers.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 536–557.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Benefit names only; none of the ER’s Magnitude figures carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content remains in any benefit item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers contain items in the ER, so none needed hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All six ER risk headings appear in their correct tiers.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 603–620.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Risk names only; the ER’s 64% anaphylaxis figure and dose-relationship detail are omitted as required.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content remains in any risk item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers contain items in the ER, so none needed hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Marker names, targets and rationales track the ER Monitoring Protocol & Defining Success table (ER lines 449–459).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER table rows are present as marker_1 through marker_9, with targets unchanged.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 759–763 reproduce the ER’s 4/8/12-week, 6-month, annual and 12/24-week photographic schedule.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items come from the ER’s qualitative-marker bullet list (ER lines 463–473).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	Six of six carried over: nocturia diary, urgency/leakage, stream and emptying, sleep continuity, shedding/coverage, digestive tolerance.

Issues 16/08/2026 03:11

Pass rate 100.00%. No issues found.

Issues 16/08/2026 03:02

1. 1.2 — Allergy hedge dropped from At-A-Glance: The ER Conclusion (line 499) says “a genuine, if uncommon, seed allergy”; the QRS at_a_glance (line 438) reduces this to “seed allergy is the serious concern”, dropping the ER’s “if uncommon” hedge.
2. 4.5 — Content overflows one A4 page: The sheet renders to roughly two A4 pages — the Key Interactions gate wraps to ~18 lines (lines 585–601) and the Monitoring block to ~28 line-equivalents (lines 646–776) — so several sections were not condensed to the per-section budget.

Fixes 16/08/2026 03:02

1. 1.2 — Allergy hedge restored: at_a_glance now reads “seed allergy, though uncommon, is the serious concern”, restoring the ER Conclusion’s “if uncommon” hedge; “about six months” was trimmed to “six months” to hold the section at 59 words.
2. 4.5 — Key Interactions condensed: Parenthetical drug lists were trimmed to the leading examples (e.g., “warfarin, apixaban, clopidogrel” to “warfarin, clopidogrel”; “amlodipine, lisinopril, hydrochlorothiazide” to “amlodipine, lisinopril”) and the PSA item shortened to “Deferring prostate-specific antigen screening or biopsy”, cutting the gate from ~18 to ~13 wrapped lines.
3. 4.5 — Protocol and Time-to-Effect subs shortened: action_1_sub to “Divided capsules, twice daily”, action_2_sub to “Also tested: 500 mg/day oil-free extract; 5 g twice daily ground seed”, action_3_sub to “Standard where nocturia is the complaint; no timing dependence for hair”, and time_2_sub to “Improves to 12 months; no study separated before 8 weeks”.
4. 4.5 — Monitoring cells tightened: Seven marker_#_why values and two marker_#_target values were shortened without changing their meaning or any numeric range, and the cadence line was trimmed to two rendered lines; all nine marker names were left verbatim.
5. 4.5 — Benefits and Qualitative Assessment condensed: The Low benefit string dropped redundant wording (“improved arterial stiffness” to “arterial stiffness”, “postprandial glucose response” to “postprandial glucose”), and qualitative items 3 and 5 were shortened to single rendered lines each.